Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Outlook Therapeutics ( (OTLK) ) has shared an announcement.
On April 21, 2026, Outlook Therapeutics announced that it had completed a Federal Dispute Resolution meeting with the FDA’s Office of New Drugs regarding the complete response letter issued on December 30, 2025 for its biologics license resubmission for ONS-5010/LYTENAVA, an investigational bevacizumab ophthalmic formulation for wet AMD. The company said it expects a formal FDA decision from this dispute process in May 2026 and plans to update stakeholders once it receives the agency’s response, a key step that could determine the U.S. regulatory path and influence its ability to align its growing European commercial presence with a future American launch.
The most recent analyst rating on (OTLK) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
Spark’s Take on OTLK Stock
According to Spark, TipRanks’ AI Analyst, OTLK is a Neutral.
Overall score is weighed down primarily by very weak financial performance (large losses, negative equity, heavy cash burn) and negative financing/listing-related corporate events (dilution, refinancing, Nasdaq bid-price noncompliance). Technicals are broadly bearish (below longer-term averages, negative MACD), while valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on OTLK stock, click here.
More about Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration (wet AMD). LYTENAVA is the first ophthalmic bevacizumab to secure marketing authorization from both the European Commission and the UK’s MHRA for wet AMD, and the company has begun commercial launches in Germany and the UK.
In the U.S., ONS-5010/LYTENAVA remains investigational and, if approved, would become the first authorized ophthalmic bevacizumab product for retinal indications, positioning Outlook Therapeutics to formalize a treatment category that is currently served largely by off-label use.
Average Trading Volume: 2,655,253
Technical Sentiment Signal: Sell
Current Market Cap: $28.56M
Find detailed analytics on OTLK stock on TipRanks’ Stock Analysis page.